Myeloperoxidase influences the complement regulatory function of modified C-reactive protein

Innate Immunity

Volumn 20, Issue 4, 2014, Pages 440-448

  Xu, Peng Cheng ^a,b   Li, Zhi Ying ^a   Yang, Xiao Wei ^a   Zhao, Ming Hui ^a   Chen, Min ^a  

^a BEIJING HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

anti neutrophil cytoplasmic Ab; C reactive protein; complement; Myeloperoxidase; vasculitis

Indexed keywords

C REACTIVE PROTEIN; CERULOPLASMIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT FACTOR H; MODIFIED C REACTIVE PROTEIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTAMERIC CRP; UNCLASSIFIED DRUG; COMPLEMENT; PEROXIDASE; PROTEIN BINDING;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME RELEASE; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; COMPLEMENT CLASSICAL PATHWAY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEUTROPHIL;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; C-REACTIVE PROTEIN; CERULOPLASMIN; COMPLEMENT C1Q; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOMODULATION; NEUTROPHILS; PEROXIDASE; PROTEIN BINDING;

EID: 84898939840     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913508164     Document Type: Article

References (43)

1. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoAbs. Am J Pathol. 2007 ; 170: 52-64
2. Hao J, Meng LQ, Xu PC, et al. p38MAPK, ERK and PI3K Signaling Pathways Are Involved in C5a-Primed Neutrophils for ANCA-Mediated Activation. PLoS One. 2012 ; 7: e38317 - e38317
3. Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibodies associated pauci-immune vasculitis. J Clin Immunol. 2009 ; 29: 282-291
4. Gou SJ, Yuan J, Chen M, et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-Associated vasculitis. Kidney Int. 2013 ; 83: 129-137
5. Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-Associated vasculitis. Arthritis Res Ther. 2012 ; 14: R140 - R140
6. Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011 ; 117: 1340-1349
7. Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-Antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol. 1997 ; 8: 386-394
8. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990 ; 87: 4115-4119
9. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997 ; 337: 1512-1523
10. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002 ; 110: 955-963
11. Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009 ; 15: 623-625
12. Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012 ; 64: 3452-3462
13. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxydase, a leukocyte-derived vascular NO oxidase. Science. 2002 ; 296: 2391-2394
14. Hind CR, Winearls CG, Lockwood CM, et al. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol. 1984 ; 21: 341-345
15. Kälsch AI, Csernok E, Münch D, et al. Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol. 2010 ; 37: 2319-2325
16. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004 ; 279: 48487-48490
17. Potempa LA, Maldonado BA, Laurent P, et al. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol. 1983 ; 20: 1165-1175
18. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol. 1998 ; 30: 1415-1426
19. Ji SR, Wu Y, Zhu L, et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 2007 ; 21: 284-294
20. Motie M, Schaul KW, Potempa LA. Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. Drug Metab Dispos. 1998 ; 26: 977-981
21. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009 ; 105: 128-137
22. Mihlan M, Stippa S, Józsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009 ; 16: 1630-1640
23. Mihlan M, Blom AM, Kupreishvili K, et al. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J. 2011 ; 25: 4198-4210
24. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation. 2004 ; 109: 1870-1876
25. Ji SR, Wu Y, Potempa LA, et al. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2006 ; 26: 935-941
26. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 ; 65: 1-11
27. Zhao MH, Lockwood CM. A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods. 1996 ; 197: 121-130
28. Xu PC, Cui Z, Chen M, et al. Comparison of characteristics of natural autoAbs against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology (Oxford). 2011 ; 50: 1236-1243
29. Taylor KE, van den Berg CW. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology. 2007 ; 120: 404-411
30. Xu PC, Chen M, Cui Z, Zhao MH. Influence of myeloperoxidase by anti-myeloperoxidase antibodies and its association with the disease activity in microscopic polyangiitis. Rheumatology (Oxford). 2010 ; 49: 2068-2075
31. Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009 ; 15: 623-625
32. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem. 2009 ; 55: 361-364
33. Xu PC, Hao J, Yang XW, et al. C-reactive protein enhances the respiratory burst of neutrophils-induced by antineutrophil cytoplasmic Ab. Mol Immunol. 2012 ; 52: 148-154
34. Khreiss T, József L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res. 2005 ; 97: 690-697
35. Lee RT, Lee YC. Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site. Glycobiology. 2003 ; 13: 11-21
36. Lee RT, Lee YC. Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide. Glycoconj J. 2006 ; 23: 317-327
37. Köttgen E, Hell B, Kage A, Tauber R. Lectin specificity and binding characteristics of human C-reactive protein. J Immunol. 1992 ; 149: 445-453
38. Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol. 2011 ; 6: 93-100
39. Khreiss T, József L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res. 2005 ; 97: 690-697
40. Schwedler SB, Guderian F, Dämmrich J, et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant. 2003 ; 18: 2300-2307
41. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 2008 ; 12: 2245-2254
42. van de Goot F, Krijnen PA, Begieneman MP, et al. Acute inflammation is persistent locally in burn wounds: a pivotal role for complement and C-reactive protein. J Burn Care Res. 2009 ; 30: 274-280
43. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999 ; 190: 1733-1740